Mechelen, Belgium; 30 September 2008 - Galapagos NV (Euronext: GLPG)
announced today that it has received a transparency notification from
Delta Lloyd, disclosing that they hold a 5.4% interest in the share
capital of Galapagos.
Delta Lloyd Levensverzekeringen NV disclosed that they hold 1,145,000
shares in the share capital of Galapagos, as of 1 September 2008.
This is the first notification Galapagos has received from Delta
Lloyd Levensverzekeringen NV. Galapagos had 21,188,829 shares
outstanding as of 1 September, 2008.
"We are very pleased to welcome Delta Lloyd as a major institutional
shareholder in Galapagos," said Onno van de Stolpe, CEO. "Delta Lloyd
is a highly respected investor, and we are proud of their confidence
in the long term potential of the Company."
Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC:
GLPYY) is a drug discovery company with pre-clinical programs in bone
and joint diseases and bone metastasis. Its BioFocus DPI division
offers a full suite of target-to-drug discovery products and services
to pharmaceutical and biotech companies, encompassing target
discovery and validation, screening and drug discovery through to
delivery of pre-clinical candidates. BioFocus DPI also provides
adenoviral reagents for rapid identification and validation of novel
drug targets, compound libraries for drug screening as well as
chemogenomics and ADMET database products to select targets and
compounds. Galapagos currently employs about 500 people and operates
facilities in six countries, with global headquarters in Mechelen,
Belgium. More information about Galapagos and BioFocus DPI can be
found at www.glpg.com and www.biofocusdpi.com.
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions,
performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.